UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000028043
Receipt No. R000031912
Scientific Title Early Aggressive Intervention for Infantile Atopic Dermatitis to Prevent Development of Food Allergy: a Multicenter, Investigator-Blinded, Randomized, Parallel Group Controlled Trial
Date of disclosure of the study information 2017/07/04
Last modified on 2019/01/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Early Aggressive Intervention for Infantile Atopic Dermatitis to Prevent Development of Food Allergy: a Multicenter, Investigator-Blinded, Randomized, Parallel Group Controlled Trial
Acronym Prevention of Allergy via Cutaneous Intervention (PACI) Study
Scientific Title Early Aggressive Intervention for Infantile Atopic Dermatitis to Prevent Development of Food Allergy: a Multicenter, Investigator-Blinded, Randomized, Parallel Group Controlled Trial
Scientific Title:Acronym Prevention of Allergy via Cutaneous Intervention (PACI) Study
Region
Japan

Condition
Condition Atopic Dermatitis
Classification by specialty
Clinical immunology Pediatrics Dermatology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To verify the superiority of the early aggressive treatment over the standard treatment with a randomized controlled trial for infantile atopic dermatitis to prevent food allergy.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Presence of oral food challenge-proven IgE-mediated hen egg allergy at 28 weeks of age
Key secondary outcomes 1. Symptom score of Food challenge test at 28 weeks of age
2. Total IgE antibody serum titer at 28 weeks of age
3. Egg white, ovomucoid, milk, wheat, soy, peanut and Ara h2-specific IgE antibody serum titer at 28 weeks of age
4. Egg white, ovomucoid, milk, wheat, soy, peanut and Ara h2-specific IgG4 antibody serum titer at 28 weeks of age
5. EASI scores at 2, 4, and 8 weeks after study entry and at 28 weeks of age
6. POEM scores during the study period
7. Proportion of disease free days during the study period
8. Dose of rescue medication used during the study period
9. IDQoL at 28 weeks of age
10. DFI at 28 weeks of age
11. Presence of IgE-mediated food allergy reaction during the study
12. Presence of wheezing during the study period


Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -but assessor(s) are blinded
Control Active
Stratification YES
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking YES
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Medicine
Interventions/Control_1 A:Aggressive treatment group: Early aggressive treatment with topical anti-inflammatory drug (proactive method)
Interventions/Control_2 B:Standard treatment group: Standard treatment based on the Guidelines for the Management of Atopic Dermatitis (2016) (reactive method)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
7 weeks-old <=
Age-upper limit
13 weeks-old >=
Gender Male and Female
Key inclusion criteria Infants (7-13 weeks old) who develop an itchy rash within the previous 28 days and are diagnosed with Atopic Dermatitis based on the U.K.Working Party's diagnostic criteria
Key exclusion criteria (1)Infants born before 37 weeks of gestation
(2)Twin or multiple
(3)History of side effects from emollients (Heparinoid cream :Hirudoid Soft ointment) and/or topical corticosteroids (alclometasone dipropionate :Almeta, betamethasone valerate :Rinderon-V and/or mometasone furoate :Fulumeta).
(4)History of taking oral and/or intravenous steroids within the previous 28 days
(5)History of taking immunosuppressive agents (ciclosporin, tacrolimus, etc) and/or biologics except immunizations and/or intravenous immunoglobulin within the previous 28 days.
(6)IgE-mediated hen egg allergy
(7)Infants whose family plans to move and who may not be able to visit the study site before 28 weeks of age
(8)Parents unable to understand Japanese
(9)Unwillingness or inability to comply with the study requirements and procedures
(10)Infants with severe congenital disease and/or a disease that affects dermatological evaluation

Target sample size 650

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yukihiro Ohya
Organization National Center for Child Health and
Development
Division name Allergy Center
Zip code
Address 2-10-1, Okura, Setagayaku, Tokyo 157-8535, Japan
TEL 03-3416-0181
Email ohya-y@ncchd.go.jp

Public contact
Name of contact person
1st name
Middle name
Last name Kiwako Yamamoto-Hanada
Organization PACI Study Coordinating Office
Division name Allergy Center, National Center for Child Health and Development
Zip code
Address 2-10-1, Okura, Setagayaku, Tokyo 157-8535, Japan
TEL 03-3416-0611
Homepage URL http://www.paci-study.jp/
Email allergy_research@ncchd.go.jp

Sponsor
Institute National Center for Child Health and Development
Institute
Department

Funding Source
Organization Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 国立成育医療研究センター(東京都)
浜松医科大学医学部附属病院 (静岡県)
国立病院機構名古屋医療センター(愛知県)
国立病院機構三重病院(三重県)
国立病院機構相模原病院(神奈川県)
京都府立医科大学附属病院(京都府)
大阪府立病院機構大阪はびきの医療センター(大阪府)
藤田保健衛生大学病院(愛知県)
山口大学医学部附属病院(山口県)
慶應義塾大学病院(東京都)
公立昭和病院(東京都)
千葉大学医学部附属病院(千葉県)
近畿大学医学部附属病院(大阪府)
藤田保健衛生大学坂文種報德會病院(愛知県)
さいたま市立病院(埼玉県)
東北医科薬科大学病院(宮城県)

Other administrative information
Date of disclosure of the study information
2017 Year 07 Month 04 Day

Related information
URL releasing protocol https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0233-8
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2017 Year 02 Month 27 Day
Date of IRB
Anticipated trial start date
2017 Year 07 Month 18 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 07 Month 03 Day
Last modified on
2019 Year 01 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031912

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.